Gene polymorphisms in APOE, NOS3, and LIPC genes may be risk factors for cardiac adverse events after primary CABG

J Cardiothorac Surg. 2009 Aug 19:4:46. doi: 10.1186/1749-8090-4-46.

Abstract

Introduction: Coronary artery disease progression after primary coronary artery bypass grafting may, beside classical atherosclerosis risk factors, be depending on genetic predisposition.

Methods: We investigated 192 CABG patients (18% female, age: 60.9 +/- 7.4 years). Clinically cardiac adverse events were defined as need for reoperation (n = 88; 46%), reintervention (n = 58; 30%), or angina (n = 89; 46%). Mean follow-up time measured 10.1 +/- 5.1 years. Gene polymorphisms (ApoE, NOS3, LIPC, CETP, SERPINE-1, Prothrombin) were investigated separately and combined (gene risk profile).

Results: Among classical risk factors, arterial hypertension and hypercholesterinemia significantly influenced CAD progression. Single ApoE, NOS3 and LIPC polymorphisms provided limited information. Patients missing the most common ApoE epsilon 3 allele (5,2%), showed recurrent symptoms (p = 0,077) and had more frequently reintervention (p = 0,001). NOS3 a allele was associated with a significant increase for reintervention (p = 0,041) and recurrent symptoms (p = 0,042). Homozygous LIPC patients had a higher reoperation rate (p = 0.049). A gene risk profile enabled us to discriminate between faster and slower occurrence of cardiac adverse events (p = 0.0012).

Conclusion: Single APOE, LIPC and NOS3 polymorphisms permitted limited prognosis of cardiac adverse events in patients after CABG. Risk profile, in contrast, allowed for risk stratification.

MeSH terms

  • Apolipoproteins E / genetics*
  • Cohort Studies
  • Coronary Artery Bypass / adverse effects*
  • Disease Progression
  • Female
  • Genetic Predisposition to Disease
  • Heart Diseases / genetics*
  • Heart Diseases / prevention & control
  • Humans
  • Hypercholesterolemia / complications
  • Hypertension / complications
  • Lipase / genetics*
  • Male
  • Middle Aged
  • Nitric Oxide Synthase Type III / genetics*
  • Polymorphism, Genetic*
  • Polymorphism, Restriction Fragment Length
  • Reoperation
  • Risk Factors
  • Treatment Outcome

Substances

  • Apolipoproteins E
  • LIPC protein, human
  • Nitric Oxide Synthase Type III
  • Lipase